Oritavancin: Difference between revisions
From IDWiki
No edit summary |
No edit summary |
||
| Line 13: | Line 13: | ||
* Not required |
* Not required |
||
[[Category: |
[[Category:Lipoglycopeptides]] |
||
Latest revision as of 20:09, 31 January 2020
- Semisynthetic lipoglycopeptide antibiotic with very long half-life
Indications
- MRSA skin and soft tissue infections
Dosing
- IV once a week, long-acting
Renal Dosing
- Not required
